CA-XSOLLA
14.3.2024 15:22:26 CET | Business Wire | Press release
Xsolla, a global video game commerce company, announces its partnership with GameAnalytics, a premier analytics platform in the gaming industry. This partnership marks the beginning of a new era of in-game monetization, with the integration of Xsolla's Web Shop into the GameAnalytics platform. The initiative aims to provide game developers with next-generation tools for direct-to-consumer sales, starting with a pioneering proof of concept centered around the Xsolla Web Shop.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240314598476/en/
(Graphic: Xsolla)
"This partnership with GameAnalytics is a game-changer for developers worldwide. Combining GameAnalytics' powerful data analysis tools with Xsolla's comprehensive sales solutions provides developers with an unprecedented opportunity to understand and engage their audience directly," said Berkley Egenes, Chief Marketing Officer and Chief Growth Officer at Xsolla. "This empowers developers to maximize their revenue potential and enhances the gaming experience for players by ensuring the games they love continue to thrive."
Game developers integrate their games with GameAnalytics to access mission-critical data and uncover valuable insights about their games’ performance, including engagement and monetization data. This, above others, allows them to understand player spending behavior, optimize their revenue streams, and maximize earning potential.
"We are excited to embark on this partnership with Xsolla, a company that shares our commitment to empowering game developers," said Allison Bilas, COO at GameAnalytics. “Integrating Xsolla's Web Shop into our analytics platform opens new avenues for developers to monetize their games more effectively. This collaboration is about providing actionable insights that enable developers to craft compelling experiences for gamers while optimizing their revenue streams. It's a testament to our shared vision of supporting the growth and success of the gaming community."
Xsolla is a pivotal player in the gaming industry, collaborating with thousands of developers, publishers, and platforms, including Epic Games, Roblox, Twitch, Steam, Kabam, Niantic, EA, Warner Brothers, Wizards of the Coast, Sega, Take Two, SciPlay and Miniclip. As a merchant of record, Xsolla undertakes the risk and operational complexity associated with direct-to-consumer video game sales, addressing challenges such as chargebacks, fraud, taxes, and compliance laws. This partnership underscores Xsolla's commitment to supporting the gaming community by facilitating direct sales to consumers online, bypassing substantial platform fees associated with traditional app stores.
With the recent announcement of powering web shops for 40 of the top 100 mobile games, Xsolla continues demonstrating its dedication to innovation and support for mobile game developers. The collaboration with GameAnalytics represents a significant step forward in achieving this goal, offering developers cutting-edge tools to analyze, understand, and monetize their games effectively.
For more information about the partnership, please visit: https://xsolla.pro/xsolla-gameanalytics
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in London, Berlin, Seoul, Beijing, Kuala Lumpur, Raleigh, Tokyo, and cities around the world, Xsolla supports major gaming titles like Valve, Twitch, Roblox, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit: xsolla.com
About GameAnalytics
GameAnalytics is the leading analytics solution for indie developers, game studios, and powerhouse publishers globally. Their network covers 100,000 games played by over 1.75 billion people for an average of 24 billion monthly sessions. The GameAnalytics platform enables game development teams to rapidly refine gameplay, improve retention, and increase revenue with real-time data analysis for all major game engines and operating systems through simple SDK integration. GameAnalytics was founded in 2012 by Danish serial entrepreneur Morten E. Wulff, who remains the company's Chairman today. After raising over $8M in funding, the leading mobile advertising company, Mobvista, acquired the company in 2016. To learn more and get started for free, visit gameanalytics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240314598476/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
